Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCLMichael Northend, William Townsend, Rebecca Auer et al.|Blood Advances|2022Cited by 44
Prognostic significance of <i>FCGR2B</i> expression for the response of DLBCL patients to rituximab or obinutuzumab treatmentMałgorzata Nowicka, Mark S. Cragg, Chern Siang Lee et al.|Blood Advances|2021Cited by 18